Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 418

The DOI matches its Crossref record; 195 of the 195 references it cites were found in a registry or an index.

Biology and management of pancreatic cancer

Open access
Ghaneh, P, Costello, E, Neoptolemos, J P·2008·Postgraduate Medical Journal

Abstract

Pancreatic cancer continues to pose an enormous challenge to clinicians and cancer scientists. With a more affluent world the global incidence of pancreatic cancer is rising. For the first time significant advances are now being made into the management of the disease. There is a more sophisticated approach to palliative care and the centralisation of pancreatic cancer services is leading to greater tumour resection rates. Newer adjuvant modalities are also greatly increasing the 5 year survival rates. The molecular basis of pancreatic cancer is now better understood than ever before, leading to the development of new diagnostic approaches and the introduction of mechanistic based treatments. Technical advances in imaging and great improvements in conventional and molecular pathology have led to a deeper understanding of the pathological variables of the disease. This is now an important time for making big inroads into what still remains the most lethal of the common cancers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gut.2006.103333

Cites

195 of 195 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 195 references

Research works printed but not linked: 45

  1. Ko, 2005, Systemic therapy for pancreatic cancer, Semin Radiat Oncol, 15, 245, 10.1016/j.semradonc.2005.06.001 · doi:10.1016/j.semradonc.2005.06.001
  2. Friess, 1995, Enhanced erbB-3 expression in human pancreatic cancer correlates with tumor progression, Clin Cancer Res, 1, 1413
  3. Barton, 1991, Transforming growth factor alpha and epidermal growth factor in human pancreatic cancer, J Pathol, 163, 111, 10.1002/path.1711630206 · doi:10.1002/path.1711630206
  4. Anonymous, 2004, SWOG S0502: phase lll randomized study of gemcitabine with versus without cetuximab as first-line therapy in patients with locally advanced unresectable or metastatic adenocorcinoma of the pancreas, Clin Adv Hematol Oncol, 2, 201
  5. de Jonge, 2006, Multiple targeted tyrosine kinase inhibition in the clinic: all for one or one for all?, Eur J Cancer, 42, 1351, 10.1016/j.ejca.2006.02.013 · doi:10.1016/j.ejca.2006.02.013
  6. Zapatka, 2007, Basement membrane component laminin-5 is a target of the tumor suppressor Smad4, Oncogene, 25, 1417, 10.1038/sj.onc.1209918 · doi:10.1038/sj.onc.1209918
  7. Narita, 1984, Ataxia-telangiectasia with dysgerminoma of right ovary, papillary carcinoma of thyroid, and adenocarcinoma of pancreas, Cancer, 54, 1113, 10.1002/1097-0142(19840915)54:6<1113::AID-CNCR2820540632>3.0.CO;2-C · doi:10.1002/1097-0142(19840915)54:6<1113::aid-cncr2820540632>3.0.co;2-c
  8. Seket, 2003, Pancreatic acinar cell carcinoma in a patient with familial adenomatous polyposis, Gastroenterol Clin Biol, 27, 818
  9. Sudo, 2005, Development of an introductal papillary-mucinous neoplasm of the pancreas in a patient with familial adenomatous polyposis, Pancreas, 31, 428, 10.1097/01.mpa.0000183378.04295.27 · doi:10.1097/01.mpa.0000183378.04295.27
  10. Klöppel, 1996, World Health Organization international histological typing of tumors of the exocrine pancreas, 1
  11. Holen, 2002, Clinical characteristics and outcomes from on institutional series of acinar cell carcinoma of the pancreas and related tumors, J Clin Oncol, 20, 4673, 10.1200/JCO.2002.02.005 · doi:10.1200/jco.2002.02.005
  12. Seo, 2006, Solid-pseudopapillary tumor of the pancreas, J Clin Gastroenterol, 40, 919, 10.1097/01.mcg.0000225671.91722.10 · doi:10.1097/01.mcg.0000225671.91722.10
  13. Dhebri, 2004, Diagnosis, treatment and outcome of pancreatoblastoma, Pancreatology, 4, 441, 10.1159/000079823 · doi:10.1159/000079823
  14. Royal College of Pathologists, 2002, Standards and minimum datasets for reporting cancers. Minimum dataset for histopathological reporting of pancreatic, ampulla of vater and bile duct carcinoma
  15. Neoptolemos, 2005, Is endoscopic ultrasonography superior to multidetector CT for assessing pancreatic cancer?, Nat Clin Pract Oncol, 2, 78, 10.1038/ncponc0096 · doi:10.1038/ncponc0096
  16. Louhimo, 2004, Serum HCG beta and CA 72–4 are stronger prognostic factors than CEA, CA 19-9 and CA 242 in pancreatic cancer, Oncology, 66, 126, 10.1159/000077438 · doi:10.1159/000077438
  17. Ozkan, 2006, Significance of serum receptor-binding cancer antigen (RCAS) in pancreatic cancer and benign pancreatobiliaty diseases, Pancreatology, 6, 268, 10.1159/000092687 · doi:10.1159/000092687
  18. Hanninen, 2005, Magnetic resonance cholangiopancreatography: image quality, ductal morphology, and value of additional T2-and T1-weighted sequences for the assessment of suspected pancreatic cancer, Acta Radiol, 46, 117, 10.1080/02841850510020941 · doi:10.1080/02841850510020941
  19. Hanninen, 2002, Prospective evaluation of pancreatic tumours: accuracy of MR imaging with MR cholangiopancreotography and MR angiography, Radiology, 224, 34, 10.1148/radiol.2241010798 · doi:10.1148/radiol.2241010798
  20. Wittmann, 2006, Endoscopic ultrasound-guided tissue sampling by combined fine needle aspiration and trucut needle biopsy: a prospective study, Cytopathology, 17, 27, 10.1111/j.1365-2303.2006.00313.x · doi:10.1111/j.1365-2303.2006.00313.x
  21. Doran, 2004, Laparoscopy and laparoscopic ultrasound in the evaluation of pancreatic and periampullary tumours, Dig Surg, 21, 305, 10.1159/000080885 · doi:10.1159/000080885
  22. Connor, 2005, Serum CA19-9 measurement increases the effectiveness of staging laparoscopy in patients with suspected pancreatic malignancy, Dig Surg, 22, 80, 10.1159/000085297 · doi:10.1159/000085297
  23. Eguchi, 2006, Patients with pancreatic intraductal papillary mucinous neoplasms are at high risk of colorectal cancer development, Surgery, 139, 749, 10.1016/j.surg.2005.11.008 · doi:10.1016/j.surg.2005.11.008
  24. Suleyman Ozyalcin, 2004, Efficacy of coeliac plexus and splanchnic nerve blockades in body and tail located pancreatic cancer pain, Eur J Pain, 8, 539, 10.1016/j.ejpain.2004.01.001 · doi:10.1016/j.ejpain.2004.01.001
  25. Leksowski, 2001, Thoracoscopic splanchnicectomy for control of intractable pain due to advanced pancreatic cancer, Surg Endosc, 15, 129, 10.1007/s004640090009 · doi:10.1007/s004640090009
  26. Bruno, 1998, Placebo controlled trial of enteric coated pancreatin microsphere treatment in patients with unresectable cancer of the pancreatic head region, Gut, 42, 92, 10.1136/gut.42.1.92 · doi:10.1136/gut.42.1.92
  27. Prat, 1998, Predictive factors for survival of patients with inoperable malignant distal biliary strictures: a practical management guideline, Gut, 42, 76, 10.1136/gut.42.1.76 · doi:10.1136/gut.42.1.76
  28. Kuriansky, 2000, Simultaneous laparoscopic biliary and retrocolic gastric bypass in patients with unresectable carcinoma of the pancreas, Surg Endosc, 14, 179, 10.1007/s004649900095 · doi:10.1007/s004649900095
  29. Cunningham, 2005, Phase lll randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer, Eur J Cancer, 3, (Suppl
  30. Smith, 2006, Capecitabine in carcinoma of the pancreas, Expert Opin Pharmacother, 7, 1633, 10.1517/14656566.7.12.1633 · doi:10.1517/14656566.7.12.1633
  31. Chauffert, 2006, Phase III trial comparing initial chemorodiotherapy (intermittent cisplatin and infusional 5-FU) followed by gemcitabine vs. gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer: a FFCD-SFRO study, J Clin Oncol, 4008, 10.1200/jco.2006.24.18_suppl.4008 · doi:10.1200/jco.2006.24.18_suppl.4008
  32. Genentech, Phase III study of Avastin in odvanced pancreatic cancer does not meet primary endpoint
  33. Roche, Clinical trial protocol registry and results database
  34. National Cancer Institute, GV1001 and gemcitabine in sequential combination to gemcitabine monotherapy in pancreatic cancer
  35. National Cancer Institute, Phase III randomized study of chemoimmunotherapy comprising gemcitabine hydrochloride and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer
  36. Settmacher, 2004, Reconstruction of visceral orteries with homografts in excision of the pancreas, Chirurg, 75, 1199, 10.1007/s00104-004-0899-4 · doi:10.1007/s00104-004-0899-4
  37. Saleh, 2002, Preoperative endoscopic stent placement before pancreaticoduodenectomy: a meta-analysis of the effect on morbidity and mortality, Gastrointest Endosc, 56, 529, 10.1016/S0016-5107(02)70438-0 · doi:10.1016/s0016-5107(02)70438-0
  38. Imamura, 2004, A randomized multicenter trial comparing resection and radiochemotherapy for resectable locally invasive pancreatic cancer, Surgery, 136, 1003, 10.1016/j.surg.2004.04.030 · doi:10.1016/j.surg.2004.04.030
  39. McKay, 2006, Meta-analysis of pancreaticojejunostomy versus pancreaticogastrostomy reconstruction after pancreaticoduodenectomy, Br J Surg, 93, 929, 10.1002/bjs.5407 · doi:10.1002/bjs.5407
  40. Winter, 2006, Does pancreatic duct stenting decrease the rate of pancreatic fistula following pancreaticoduodenectomy? Results of a prospective randomized trial, J Gastrointest Surg, 10, 1280, 10.1016/j.gassur.2006.07.020 · doi:10.1016/j.gassur.2006.07.020
  41. Lin, 1999, Prospective randomized comparison between pylorus-preserving and standard pancreatoduodenectomy, Br J Surg, 86, 603, 10.1046/j.1365-2168.1999.01074.x · doi:10.1046/j.1365-2168.1999.01074.x
  42. Takada, 2002, Is postoperative adjuvant chemotherapy useful for gall-bladder carcinoma?, Cancer, 95, 1685
  43. Kosuge, 2006, A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer, Jpn J Clin Oncol, 36, 159, 10.1093/jjco/hyi234 · doi:10.1093/jjco/hyi234
  44. Stocken, 2005, Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer, Br J Cancer, 92, 1372, 10.1038/sj.bjc.6602513 · doi:10.1038/sj.bjc.6602513
  45. Regine, 2006, RichRTOG 9704 a phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma, J Clin Oncol, 4007, 10.1200/jco.2006.24.18_suppl.4007 · doi:10.1200/jco.2006.24.18_suppl.4007

Cited by

See all 418

Metadata

Authors
Ghaneh, P., Costello, E., & Neoptolemos, J. P.
Venue
Postgraduate Medical Journal
Published
2008-09-01
Volume
84
Issue
995
Pages
478-497
ISSN
  • 0032-5473 (ISSN-L)
  • 1469-0756
OpenAlex
W2133667676
Cited by
418
References
195
FWCI
14.79
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Biology and management of pancreatic cancer. https://app.cochat.ai/papers/10.1136/gut.2006.103333
The paper
Ghaneh, P., Costello, E., & Neoptolemos, J. P. (2008). Biology and management of pancreatic cancer. Postgraduate Medical Journal. https://doi.org/10.1136/gut.2006.103333

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.